466 related articles for article (PubMed ID: 29667463)
1. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
2. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
3. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
7. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].
Hu RZ; Zhao SQ; Shen B; Guo GB
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):634-637. PubMed ID: 31594082
[No Abstract] [Full Text] [Related]
10. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
11. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
14. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
[TBL] [Abstract][Full Text] [Related]
16. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
Yang T; Xing H; Wang G; Wang N; Liu M; Yan C; Li H; Wei L; Li S; Fan Z; Shi M; Chen W; Cai S; Pawlik TM; Soh A; Beshiri A; Lau WY; Wu M; Zheng Y; Shen F
Clin Chem; 2019 Dec; 65(12):1543-1553. PubMed ID: 31672853
[TBL] [Abstract][Full Text] [Related]
17. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
18. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
19. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
20. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.
Ricco G; Cavallone D; Cosma C; Caviglia GP; Oliveri F; Biasiolo A; Abate ML; Plebani M; Smedile A; Bonino F; Pontisso P; Brunetto MR
Cancer Biomark; 2018 Feb; 21(3):603-612. PubMed ID: 29278878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
